Clenbuterol

A veterinary bronchodilator (and asthma drug in some countries) misused for fat loss. It raises metabolic rate through beta-2 receptor stimulation. Toxicity has occurred at amounts overlapping therapeutic asthma exposure, so there is no clean line between a medical amount and a dangerous one — the long half-life and accumulation matter more.

Clenbuterol is a beta-2 agonist, the same drug class as an asthma reliever inhaler, but far longer-acting. It stimulates beta-2 receptors on fat cells and muscle. Beta-agonist fat breakdown and the muscle-sparing effect are established in laboratory and livestock work; neither has been shown to produce meaningful fat loss in a controlled trial in healthy humans, because no such trial exists. It is a veterinary bronchodilator and a livestock growth agent in some countries, and an asthma medicine in others — it has never been approved for human use in the United States. The thermogenic effect is real, which is precisely why the cardiac and neurological side effects are also real: you cannot stimulate that receptor system for weeks without consequences elsewhere.

Human asthma data proves the mechanism; livestock data documents the repartitioning effect. Controlled fat-loss trials in healthy humans do not exist — the practice runs entirely on veterinary pharmacology plus community lore.

• There is no randomised trial of clenbuterol for fat loss or physique in healthy humans. The evidence base people rely on is animal work — mostly livestock — plus a small human literature in muscle-wasting conditions.
• The livestock growth data is real but was generated at doses and in species that do not translate, and the muscle-sparing effect seen in animals has not been replicated convincingly in healthy humans.
• What does exist in humans is a substantial poisoning literature: case series of tachycardia, tremor, palpitations, chest pain, hypokalaemia and hospital admission, including outbreaks from contaminated meat and from bodybuilding use.
• Case reports document myocardial infarction and serious arrhythmia in young users with no other cardiac risk factors.
• Animal studies show cardiac hypertrophy and heart-muscle cell death at sustained doses, which is the mechanistic backdrop to the human case reports.

Very long half-life for its class, roughly 26-36 hours, which is the crux of its danger: the stimulation does not switch off between doses and accumulates. Effects on heart rate and tremor persist for days after stopping. It is a banned substance in all tested sport. Receptor downregulation is genuine — the thermogenic effect fades within weeks — which is why users escalate doses, which is exactly when the cardiac events cluster.

Cardiac by mechanism, not by accident: tremors, tachycardia, arrhythmias, and documented myocardial injury case reports — including in young, otherwise healthy users. Can cause hypokalemia (the cramps are a warning, not an inconvenience); taurine depletion reported in animal studies has not been established clinically in humans. Long half-life (~36 h) means a stimulant that never clocks out; poison-control literature features it regularly.

• Anyone with any cardiovascular condition, arrhythmia, or a family history of sudden cardiac death
• Anyone with hyperthyroidism
• Anyone taking other stimulants, including high caffeine intake
• Anyone pregnant or breastfeeding
• Anyone competing in tested sport
• Anyone with an anxiety disorder, which it reliably worsens

• Any other stimulant — caffeine, ephedrine, amphetamines, yohimbine — stacks cardiovascular risk in the most direct way possible.
• Beta-blockers, which oppose it directly and are also what a hospital may need to use.
• Potassium-lowering drugs such as thiazide and loop diuretics, compounding the hypokalaemia risk.
• Thyroid hormone, which is a common and particularly dangerous stack because both raise cardiac demand.
• Anything that prolongs the QT interval on an ECG.

Documented interactions with other things people research. A compound not listed here does not mean the combination is safe — only that no specific interaction is on file.

• Heart rate and rhythm — a persistently racing heart is a hallmark of clenbuterol TOXICITY, not an expected background state to monitor through. Most reported toxic exposures in published series needed hospital care.
• Blood pressure.
• Serum potassium, since clenbuterol drives potassium into cells and hypokalaemia is a documented cause of dangerous arrhythmia here.
• Any chest pain, fainting or palpitation that is new — these are emergency symptoms, not side effects to push through.
• Sleep, tremor and anxiety, which are the dose-limiting nuisances for most people.

Toxic effects can persist for one to eight days after the last dose because of the long half-life, so stopping does not end exposure. Serious outcomes reported include seizures, heart-muscle injury, cardiac arrest and death. There is no reliable recovery timetable to offer, and framing the aftermath as the return of appetite would trivialise what is, in the published literature, an acute poisoning. Anyone with chest pain, fainting, a racing heart or serious palpitations needs emergency assessment, and should say clenbuterol was involved.

US: not a controlled substance but not approved for human use; certain uses in food-producing animals are prohibited. Banned by WADA.

Papers about this compound, not proof of the claims above. A title says what was studied, which is sometimes a negative result or a different question entirely.

• Adverse events of clenbuterol among athletes: a systematic review of case reports and case series
  Int J Legal Med, 2023
• Clenbuterol induces lean mass and muscle protein accretion, but attenuates cardiorespiratory fitness and desensitizes muscle β(2)-adrenergic signalling
  J Physiol, 2025
• Nanosensors: A smart remedy for early detection of clenbuterol contamination in food
  Food Chem, 2023

• Adverse events of clenbuterol among athletes: a systematic review of case reports and case seriesInt J Legal Med · 2023
• Clenbuterol HydrochlorideProfiles Drug Subst Excip Relat Methodol · 2017
• Clenbuterol and the horse revisitedVet J · 2009
• Abuse of clenbuterol and its detectionCurr Med Chem · 2003
• Clenbuterol-Induced Myocarditis: A Case ReportEur J Case Rep Intern Med · 2020
• Clenbuterol - A long term uterine relaxantJ Perinat Med · 1981
• Clenbuterol induces lean mass and muscle protein accretion, but attenuates cardiorespiratory fitness and desensitizes muscle β(2)-adrenergic signallingJ Physiol · 2025
• Nanosensors: A smart remedy for early detection of clenbuterol contamination in foodFood Chem · 2023
• [Clenbuterol: 'redistribution agent']Ned Tijdschr Geneeskd · 1988
• Analytical methods for the detection of clenbuterolBioanalysis · 2009
• Clenbuterol Prevents Mechanical Unloading-Induced Myocardial Atrophy via Upregulation of Transient Receptor Potential Channel-3Int Heart J · 2023
• Single-dose administration of clenbuterol is detectable in dried blood spotsDrug Test Anal · 2020